ArticleNature2025
An ultrasensitive method for detection of cell-free RNA.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Trial
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Integrative multi-omics profiling and machine learning reveal enhancer RNA signatures for early detection and prognostic stratification in breast cancer.NAR cancer · 2026Article
- Article
- Deconformer: efficient cell-type composition profiling of cfRNA across diverse cell types.Briefings in bioinformatics · 2026Article
- Multiplex RT-PCR-Based Sequencing Assay to Detect Kidney Cancer-Specific Splice Variants in Tumor Tissues and Plasma Cell-Free RNAs.Molecular diagnosis & therapy · 2026Article
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- Clinical value of blood circulating tumor RNA (ctRNA) in liquid biopsy of lung cancer: a narrative review.Translational lung cancer research · 2026Review
- Piroctone olamine promotes BECN1 transcription and activates autophagy by targeting HDAC6 in colorectal cancer.Acta pharmacologica Sinica · 2026Article
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes.iMeta · 2026Review
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026Review
- Machine learning-advanced hydrogel-based transcription-coupled positive-feedback CRISPR/Cas13a analysis for novel microRNA signatures in differential diagnosis of non-small cell lung cancer.Journal of nanobiotechnology · 2026Article
- Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Circulating RNA as a Functional Component of Liquid Biopsy in Cancer: Concepts, Classification, and Clinical Applications.International journal of molecular sciences · 2026Review
- New opportunities and challenges for nonshedder tumors.Fundamental research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Monica C Nesselbush *Stanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4818-2301
Bogdan A Luca *Department of Pathology, Stanford University, Stanford, CA, USA.
Young-Jun Jeon *Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, Republic of Korea.
Isabel JabaraStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0070-6084
Catherine B MeadorMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Andrea GarofaloStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Michael S BinkleyStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-2640-5255
Angela B HuiStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Iris van 't ErveStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3667-9185
Nova XuStanford Cancer Institute, Stanford University, Stanford, CA, USA.
William Y ShiStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Kevin J LiuStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3836-3213
Takeshi SugioStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Noah KastelowitzStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6087-0492
Emily G HamiltonStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0001-7955-6244
Chih Long LiuStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6577-5427
Mari OlsenStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Rene F BonillaStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Yi Peng WangStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Alice JiangStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-1857-0680
Brianna LauStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Jordan EichholzDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mandeep BanwaitMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Joseph Schroers-MartinStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4128-2537
Jan BoegeholzStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7196-1621
Daniel A KingDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6451-712X
Helen LuikartDivision of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.
Mohammad S EsfahaniStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Mahya MehrmohamadiStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Henning StehrDepartment of Pathology, Stanford University, Stanford, CA, USA.
Tyler RaclinStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-2720-863X
Robert TibshiraniDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA.
Kiran KhushDivision of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.
Sandy SrinivasDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Helena YuDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0377-9510
Angela J RogersDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6969-6200
Viswam S NairClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-6376-8154
James M IsbellDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7305-876X
Bob T LiDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6661-8733
Zofia PiotrowskaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-8965-6991
Aaron N HataDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6127-318X
Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3119-9334
Heather A WakeleeStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1136-980X
Andrew J GentlesDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0941-9858
Ash A AlizadehStanford Cancer Institute, Stanford University, Stanford, CA, USA. arasha@stanford.edu.ORCID 0000-0002-5153-5625
Maximilian DiehnStanford Cancer Institute, Stanford University, Stanford, CA, USA. diehn@stanford.edu.ORCID 0000-0003-2032-0581
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTranslational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Quynh-Thu Xuan Le · 2022 to 2026
$12.0MThe Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted TherapiesR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, ZOFIA PIOTROWSKA · 2009 to 2026
$5.7MCirculating Genomic Determinants of Treatment Failure in Hodgkin LymphomaR01CA257655 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2021 to 2025
$3.2MMolecularly-based outcome and toxicity prediction after radiotherapy for lung cancerR01CA254179 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.1MAnalysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerR01CA244526 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.0MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MNCI NIH HHS P01 CA257907NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA137008NCI NIH HHS R01 CA233975NCI NIH HHS R01 CA244526NCI NIH HHS R01 CA254179NCI NIH HHS R01 CA257655
Abstract
Sensitive methods for detection of cell-free RNA (cfRNA) could facilitate non-invasive gene expression profiling and monitoring of diseases
Indexed as
Cell-Free Nucleic AcidsBlood PlateletsCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGene Expression ProfilingHumansLimit of DetectionLung NeoplasmsMaleRNA-SeqSensitivity and SpecificitySequence Analysis, RNATranscriptomeCell-Free Nucleic AcidsErbB Receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.